AbbVie seeks Restasis follow-up with small option fee for Aldeyra’s eye drops, despite a potential 'imminent' CRL
As AbbVie’s sales of its dry eye disease drug Restasis continue to slide following the first generic approval in February 2022, the Big Pharma is now making a small bet to potentially regain posture in the space, which Bausch + Lomb is eating into with its recent purchase of Novartis’ Xiidra.
AbbVie is paying Aldeyra Therapeutics $1 million in exchange for the option for the co-exclusive license to develop, manufacture and market the biotech’s eye drops, known as reproxalap, in the US. The Chicago-area pharma giant could also nab the exclusive license outside the country.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.